Amylin analogues

An amylin analogue which is a compound having the formula:

• R1—Z—R2
• wherein
• R1 is hydrogen, C1-4 acyl, benzoyl or C1-4 alkyl, or a half-life extending moiety M, wherein M is optionally linked to Z via a linker moiety L;
• R2 is OH or NHR3, wherein R3 is hydrogen or C1-3-alkyl;
• and
• Z is an amino acid sequence of formula I:
• (I)
• (SEQ ID NO:
• 3)
• Arg-Cys-X3-Thr-Ala-Thr-Cys-Ala-Thr-X10-Arg-Leu-
• Ala-X14-Phe-Leu-X17-Arg-X19-X20-Phe-Gly(Me)-Ala-
• Ile(Me)-Leu-Ser-Ser-Thr-X31-Val-Gly-Ser-X35-Thr-
• X37;
• wherein
• X3 is selected from the group consisting of Asn, Gly, Pro and Gln;
• X10 is selected from the group consisting of Gln, Asp and Glu;
• X14 is selected from the group consisting of Asp, His, Asn and Aad;
• X17 is selected from the group consisting of His, Asn, Gln, Glu, Thr, Val, Lys and Aad;
• X19-X20 is selected from the group consisting of Ser-Ser, Val-Val, Ser-Val and Val-Ser, or is absent;
• X31 is selected from the group consisting of Asp, Glu and Asn;
• X35 is selected from the group consisting of Asp, Glu, Asn, Ser, Phe, Orn, Aad, Gly and Thr;
• and
• X37 is selected from the group consisting of Pro, Apr and Hyp;
• and wherein the compound has at least one residue selected from:
• X3 is Gln;
• X14 is His, Asn or Aad;
• X17 is Asn, Gln, Glu, Thr or Aad;
• X19-X20 is Val-Ser or Ser-Val;
• and
• X35 is Ser, Phe, Orn, Aad, Gly or Thr;
• or a pharmaceutically acceptable salt thereof.